Advertisement
Advertisement
USNA
USANA Health Sciences Inc
13.58
USDSponsored
+0.03
+0.22%
Aug 24, 16:00 UTC -4
Closed
Pre-Market
13.66
+0.08
+0.60%
USNA Earnings Reports
Positive Surprise Ratio
USNA beat 25 of 42 last estimates.
60%
Next Report
Date of Next Report
Oct 19, 2026
Estimate for Q3 26 (Revenue/ EPS)
$223.40M
/$0.09
Implied change from Q2 26 (Revenue/ EPS)
+0.06%
/-228.57%
Implied change from Q3 25 (Revenue/ EPS)
+4.39%
/-160.00%
USANA Health Sciences Inc earnings per share and revenue
On Aug 04, 2026, USNA reported earnings of -0.07 USD per share (EPS) for Q2 26, missing the estimate of 0.43 USD, resulting in a -115.96% surprise. Revenue reached 223.27 million, compared to an expected 239.70 million, with a -6.85% difference. The market reacted with a -34.20% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of 0.09 USD, with revenue projected to reach 223.40 million USD, implying an decrease of -228.57% EPS, and increase of 0.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were USANA Health Sciences Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, USANA Health Sciences Inc reported EPS of -$0.07, missing estimates by -115.96%, and revenue of $223.27M, -6.85% below expectations.
How did the market react to USANA Health Sciences Inc's Q2 2026 earnings?
The stock price moved down -34.2%, changed from $22.78 before the earnings release to $14.99 the day after.
When is USANA Health Sciences Inc expected to report next?
The next earning report is scheduled for Oct 19, 2026.
What are the forecasts for USANA Health Sciences Inc's next earnings report?
Based on 3
analysts, USANA Health Sciences Inc is expected to report EPS of $0.09 and revenue of $223.40M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement